Trial Profile

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Upadacitinib (Primary) ; Corticosteroids; Fluocinolone acetonide; Hydrocortisone; Pimecrolimus; Tacrolimus
Indications Atopic dermatitis
Focus Registrational; Therapeutic Use
Acronyms AD Up
Sponsors AbbVie; AbbVie Germany; Sumitomo Pharma America

26 Sep 2025 Planned End Date changed from 16 Nov 2030 to 23 Oct 2030.
02 May 2024 Results (n=901) assessing analysis of efficacy and safety of Upadacitinib published in the Journal of Dermatological Treatment.
11 Apr 2024 Planned number of patients changed from 890 to 1500.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com